Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2073-2084

  Fehm, Tanja ^a   Sagalowsky, Arthur ^b   Clifford, Edward ^b   Beitsch, Peter ^b   Saboorian, Hossein ^b   Euhus, David ^b   Meng, Songdong ^a   Morrison, Larry ^c   Tucker, Thomas ^a   Lane, Nancy ^a   Ghadimi, B Michael ^d   Heselmeyer Haddad, Kerstin ^d   Ried, Thomas ^d   Rao, Chandra ^e   Uhr, Jonathan ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c ABBOTT LABORATORIES   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Immunicon Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CARCINOMA; CARCINOMA; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; COLON CARCINOMA; EPITHELIUM CELL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOFLUORESCENCE; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; CANCER STAGING; CHROMOSOME ABERRATION; COMPARATIVE STUDY; FEMALE; GENETICS; HUMAN CHROMOSOME; MALE; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR EMBOLISM;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; COMPARATIVE STUDY; CYTOGENETIC ANALYSIS; DNA, NEOPLASM; EPITHELIAL CELLS; FEMALE; HUMAN; IN SITU HYBRIDIZATION, FLUORESCENCE; KERATIN; MALE; NEOPLASM CIRCULATING CELLS; NEOPLASM STAGING; NEOPLASMS; RECEPTOR, ERBB-2; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS; KERATINS;

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KERATIN;

EID: 0035992272     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Isolation of prostate-derived single cells and cell clusters from human peripheral blood
2. Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS
3. Breast cancer cells in the blood: A pilot study
4. High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood
5. Detection of breast cancer micrometastases in peripheral blood using immunomagnetic separation and immunocytochemistry
6. Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system
7. Identification and characterization of circulating prostate carcinoma cells
8. Detection of disseminated tumor cells in peripheral blood of colorectal cancer patients
9. Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease
10. Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics
11. Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20
12. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques
13. Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients
14. Immunocytochemical detection and phenotypic characterization of micrometastatic tumour cells in bone marrow of patients with prostate cancer
15. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow
16. Sensitive fluorescent in situ hybridization method for the characterization of breast cancer cells in bone marrow aspirates
17. Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant
18. Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization
19. Molecular cytogenetic analysis of cytokeratin 20-labeled cells in primary tumors and bone marrow aspirates from colorectal carcinoma patients
20. Cytokeratin-positive cells in the bone marrow and survival of patients with I, II, or III breast cancer
21. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: Clinical outcome during long-term follow-up
22. Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer patients
23. Frequency and prognostic significance of isolated tumor cells in bone marrow of patients with non-small-cell lung cancer without overt metastases
24. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status
25. Peripheral blood tumor cell load reflects the clinical activity of the disease in patients with carcinoma of the breast
26. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
27. First-line single-agent Herceptin (trastuzumab) in metastatic breast cancer: A preliminary report
28. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
29. Standardization of the immunocytochemical detection of cancer cells in BM and blood. I. Establishment of objective criteria for the evaluation of immunostained cells
30. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction
31. Detection of epithelial cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction
32. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction
33. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow
34. Molecular detection of micrometastases and circulating tumor cells in melanoma prostatic and breast carcinomas
35. Detection and characterization of carcinoma cells in the blood
36. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: A phenotype/genotype correlation
37. Common patterns of genetic evolution in human solid tumors
38. Somatic genetic changes in human breast cancer
39. Genetic alterations in breast cancer
40. Chromosome-specific aneusomy in carcinoma of the breast
41. Analysis of numerical aberrations of specific chromosomes by fluorescent in situ hybridization as a diagnostic tool in breast cancer
42. Instability of chromosomes 1, 3, 16 and 17 in primary breast carcinomas inferred by fluorescence in situ hybridization
43. Aneuploidy of chromosome 8 as detected by interphase fluorescence in situ hybridization is a recurrent finding in primary and metastatic breast cancer
44. Genetic alterations of chromosome 17 in human breast carcinoma studied by fluorescence in situ hybridization and molecular DNA techniques
45. Interphase cytogenetics reveals a high incidence of aneuploidy and intra-tumour heterogeneity in breast cancer
46. Aneuploidy in breast cancer: A fluorescence in situ hybridization study
47. Comparison of chromosomal aberrations detected by fluorescence in situ hybridization with clinical parameters. DNA ploidy and Ki 67 expression in renal cell carcinoma
48. Trisomy 3 in renal cell carcinoma
49. Karotype analysis and marker chromosomes of renal cell carcinoma
50. Interphase cytogenetics and flow cytometry analyses of renal tumours
51. Detection of chromosomal aneuploidy by interphase fluorescence in situ hybridization in bronchoscopically gained cells from lung cancer patients
52. Detection of aneuploidy in interphase nuclei from non-small cell lung carcinomas by fluorescence in situ hybridization using chromosome-specific repetitive DNA probes
53. Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung
54. Alteration of numerical chromosomal aberrations during progression of colorectal tumors revealed by a combined fluorescence in situ hybridization and DNA ploidy analysis of intratumoral heterogeneity
55. Chromosomes 8, 12, and 17 copy number in Astler-Coller stage C colon cancer in relation to proliferative activity and DNA ploidy
56. Comparative genomic analysis of tumors: Detection of DNA losses and amplification
57. Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization
58. Gain and loss of chromosomes 1, 7, 8, 10, 18, and Y in 46 prostate cancers
59. Interphase cytogenctic analysis of prostatic carcinomas by use of nonisotopic in situ hybridization
60. Detection of numerical chromosomal abnormalities in malignant cells in fine needle aspirates by fluorescence in situ hybridization of interphase cell nuclei with chromosome-specific probes
61. Interphase cytogenetics: Analysis of numerical chromosome aberrations in isolated cells
62. Patterns of aneusomy for three chromosomes in individual cells from breast cancer tumors
63. Clone heterogeneity in diploid and aneuploid breast carcinomas as detected by FISH
64. p53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients